Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen Meghna A Singhania30 April 2019 10:16 AM ISTGlenmark will commercialize Remogliflozin in India under the brand names 'Remo' and 'Remozen'.Mumbai: In a major relief to diabetics, Glenmark...
Diabetes Treatment: CDSCO expert panel marketing authorization Nod to Glenmark's SGLT2 Inhibitor Remogliflozin etabonate Meghna A Singhania31 March 2019 1:39 PM ISTNew Delhi: Mumbai-based Glenmark Pharmaceuticals Limited recently received the permission from the IND Committee of the Central Drugs Standard...
Setback: USFDA rejects Sanofi, Lexicon Sotagliflozin for type 1 diabetes Farhat Nasim24 March 2019 9:45 AM ISTThe decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin,...
SGLT2 inhibitors can lead to serious genital infection: USFDA warning Ruby Khatun Khatun31 Aug 2018 4:50 PM ISTThe SGLT2 inhibitors approved by the FDA include Johnson and Johnson's Invokana, Eli Lilly & Co's Jardiance, as well as those from Bristol-Myers...
